STAT China: Big news at Simcere, and a breakthrough designation for Legend Biotech
A version of this digest first appeared in the weekly STAT China newsletter. To receive future editions, sign up here.
Good day and thanks for joining us this week for STAT China. Just as Chinese Covid-19 vaccine developers look to other countries to host their late-stage trials, a major global pharma in the vaccine race added a Chinese partner last week. The country also endorsed a CAR-T project, and another biotech is reportedly mulling a Hong Kong IPO later this year.
